Search Clinical Trials
By Condition
By Location (USA)
By Location (Other)
By Sponsor
Resources
Privacy Policy
About Us
Disclaimer
Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme Clinical Trials Facts presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, travels to or treatment with a real dr.. We aren't doctors. Always consult your mD on Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme Clinical research trials and Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme medical trials occur in many of places across the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectiveness of new does drugs. The role of the studies / undertakings is to figure out certain human healthcare questions. Clinical trials are a popular means for doctors, government agencies, and private sector corporations to locate treatments for all forms of circumstances, including Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme. Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme Clinical Trials and other clinical trials permit volunteers to get medical treatment options before they are available to the masses. Most times the human subjects acquire treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme clinical trial. Participants oftentimes recieve the finest healthcare available for their Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme condition. Dangers are a reality, nonetheless, and might include extra or frequent physician calls, health hazards (potentially life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.

Home > "C" Clinical Trials Conditions > Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme



Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

For Condition: adult glioblastoma multiforme
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) , Duke Comprehensive Cancer Center
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. O6-benzylguanine may increase the effectiveness of carmustine by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of combining carmustine with O6-benzylguanine in treating patients who have newly diagnosed supratentorial glioblastoma multiforme.
Details: OBJECTIVES: I. Determine the activity of carmustine and O6-benzylguanine in patients with newly diagnosed supratentorial glioblastoma multiforme not requiring immediate radiotherapy. II. Determine the toxicity of this regimen in these patients. PROTOCOL OUTLINE: Patients receive O6-benzylguanine IV over 1 hour followed approximately 1 hour later by carmustine IV over 1 hour on day 1. Treatment repeats every 6 weeks for a maximum of 3 courses in the absence of disease progression or unacceptable toxicity. Patients are then referred for radiotherapy. Patients who demonstrate tumor response after completion of the third course of chemotherapy receive 6 additional courses after completion of radiotherapy. PROJECTED ACCRUAL: A total of 19-36 patients will be accrued for this study.
Eligibility:
Study Type:
  Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: 
Protocol Entry Criteria: PROTOCOL ENTRY CRITERIA: --Disease Characteristics-- - Histologically confirmed newly diagnosed supratentorial glioblastoma multiforme not requiring immediate radiotherapy - Measurable residual disease on a contrast-enhanced MRI or CT scan (for patients with a medical contraindication for MRI) with a baseline scan obtained at the corticosteroid dose the patient is receiving on the day of treatment --Prior/Concurrent Therapy-- Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: - See Disease Characteristics - Concurrent corticosteroids allowed if on stable dose for 3 days before study Radiotherapy: See Disease Characteristics Surgery: No more than 28 days since prior surgical resection or biopsy --Patient Characteristics-- Age: 18 and over Performance status: Karnofsky 60-100% Life expectancy: Not specified Hematopoietic: - Absolute granulocyte count at least 1,500/mm3 - Platelet count at least 100,000/mm3 - Hemoglobin greater than 10 g/dL Hepatic: - Bilirubin normal - SGOT no greater than 2.5 times upper limit of normal Renal: - Creatinine no greater than 1.5 mg/dL - BUN no greater than 25 mg/dL Pulmonary: DLCO greater than 75% predicted Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception during and for 2 months after study
Total Enrollment: 

Location and Contact Information:

Overall Study Official:
HenryFriedman,  Study Chair,  Duke Comprehensive Cancer Center


Additional Information:
Study ID Numbers:
  CDR0000256332;  DUMC-3318-01-12,NCI-5632
Study Start Date: 
Record last reviewed: August 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00046878

Other Adult Glioblastoma Multiforme Studies:
1. Temozolomide and Carmustine in Treating Patients With Anaplastic Glioma

2. Taurolidine in Treating Patients With Recurrent or Progressive Glioma

3. Temozolomide in Treating Patients With Recurrent Malignant Glioma

4. Radiation Therapy in Treating Patients With Glioblastoma

5. Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme

Related Studies:

Other adult glioblastoma multiforme Clinical Trials
Other Clinical Trials
Other Clinical Trials

Carmustine and O6-Benzylguanine in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme

Modify your Search

  Other adult glioblastoma multiforme Clinical Trials
  Other Clinical Trials
  Other Clinical Trials


Warning: include(/var/www/cgi-bin/traxis/counter.php) [function.include]: failed to open stream: No such file or directory in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103

Warning: include() [function.include]: Failed opening '/var/www/cgi-bin/traxis/counter.php' for inclusion (include_path='.:/usr/local/lib/php') in /home/cts/domains/clinicaltrialssearch.org/public_html/index.php on line 103